Induction therapy in lung transplantation

Transplant International

Volumn 26, Issue 7, 2013, Pages 696-703

  Sweet, Stuart C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

immunosuppression; induction; lung clinical; tolerance

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC REACTION; ANAPHYLAXIS; ASEPTIC MENINGITIS; BRONCHIOLITIS OBLITERANS; COMPARATIVE STUDY; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; FEVER; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATURIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LONG TERM SURVIVAL; LUNG EDEMA; LUNG TRANSPLANTATION; MORTALITY; PRIORITY JOURNAL; REGISTER; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; REVIEW; RIGOR; SEIZURE; SERUM SICKNESS;

ANTIBODIES, MONOCLONAL, HUMANIZED; BRONCHIOLITIS OBLITERANS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; LYMPHOCYTE DEPLETION; RECEPTORS, INTERLEUKIN-2;

EID: 84879023426     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12115     Document Type: Review

References (57)

1. Game DS, Lechler RI,. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol 2002; 10: 101.
2. Avlonitis VS, Fisher AJ, Kirby JA, Dark JH,. Pulmonary transplantation: the role of brain death in donor lung injury. Transplantation 2003; 75: 1928.
3. Rostron AJ, Cork DM, Avlonitis VS, Fisher AJ, Dark JH, Kirby JA,. Contribution of Toll-like receptor activation to lung damage after donor brain death. Transplantation 2010; 90: 732.
4. Andrade CF, Waddell TK, Keshavjee S, Liu M,. Innate immunity and organ transplantation: the potential role of toll-like receptors. Am J Transplant 2005; 5: 969.
5. Deeks ED, Keating GM,. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs 2009; 69: 1483.
6. Taniguchi Y, Frickhofen N, Raghavachar A, Digel W, Heimpel H,. Antilymphocyte immunoglobulins stimulate peripheral blood lymphocytes to proliferate and release lymphokines. Eur J Haematol 1990; 44: 244.
7. Merion RM, Howell T, Bromberg JS,. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation 1998; 65: 1481.
8. Demirkiran A, Hendrikx TK, Baan CC, van der Laan LJ,. Impact of immunosuppressive drugs on CD4 + CD25 + FOXP3 + regulatory T cells: does in vitro evidence translate to the clinical setting? Transplantation 2008; 85: 783.
9. Yeung MY, Sayegh MH,. Regulatory T cells in transplantation: what we know and what we do not know. Transplant Proc 2009; 41: S21.
10. Todd PA, Brogden RN,. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs 1989; 37: 871.
11. Caillat-Zucman S, Blumenfeld N, Legendre C, et al,. The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells. Transplantation 1990; 49: 156.
12. Hong JC, Kahan BD,. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 2000; 20: 108.
13. Halloran PF,. Immunosuppressive drugs for kidney transplantation. New Engl J Med 2004; 351: 2715.
14. Ciancio G, Burke GW 3rd,. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008; 8: 15.
15. van Loenhout KC, Groves SC, Galazka M, et al,. Early outcomes using alemtuzumab induction in lung transplantation. Interact Cardiovasc Thorac Surg 2010; 10: 190.
16. Shyu S, Dew MA, Pilewski JM, et al,. Five-year outcomes with alemtuzumab induction after lung transplantation. J Heart Lung Transplant 2011; 30: 743.
17. Magliocca JF, Knechtle SJ,. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006; 19: 705.
18. Weaver TA, Kirk AD,. Alemtuzumab. Transplantation 2007; 84: 1545.
19. Zenapax Prescribing Information [12/27/12]. Available at: http://www.gene.com/download/pdf/zenxapax-prescribing.pdf.
20. Simulect Prescribing Information [12/27/12]. Available at: http://www.gene.com/download/pdf/zenxapax-prescribing.pdf.
21. Onrust SV, Wiseman LR,. Basiliximab. Drugs 1999; 57: 207.
22. Wiseman LR, Faulds D., Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 1999; 58: 1029.
23. Lake KD., Immunosuppressive drugs and novel strategies to prevent acute and chronic allograft rejection. Seminars in respiratory and critical care medicine 2001; 22: 559.
24. Vincenti F, Kirkman R, Light S, et al,. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group [see comments]. New Engl J Med 1998; 338: 161.
25. Kahan BD, Rajagopalan PR, Hall M,. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999; 67: 276.
26. Beniaminovitz A, Itescu S, Lietz K, et al,. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody [see comments]. N Engl J Med 2000; 342: 613.
27. Mehra MR, Zucker MJ, Wagoner L, et al,. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005; 24: 1297.
28. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1995-2004. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD, 2005. Available at:http://optn.transplant.hrsa.gov/data/citing. asp.
29. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; 2009. Available at:http://optn.transplant.hrsa.gov/data/citing. asp.
30. Rech AJ, Vonderheide RH,. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009; 1174: 99.
31. Opelz G,. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. Transplantation 1995; 60: 1220.
32. Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI,. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 1997; 8: 1771.
33. Christie JD, Edwards LB, Kucheryavaya AY, et al,. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31: 1073.
34. Hachem RR, Edwards LB, Yusen RD, Chakinala MM, Alexander PG, Trulock EP,. The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry. Clin Transplant 2008; 22: 603.
35. Trulock EP, Christie JD, Edwards LB, et al,. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. [Review] [0 refs]. J Heart Lung Transplant 2007; 26: 782.
36. Christie JD, Edwards LB, Aurora P, et al,. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report-2008. J Heart Lung Transplant 2008; 27: 957.
37. Christie JD, Edwards LB, Kucheryavaya AY, et al,. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010; 29: 1104.
38. Christie JD, Edwards LB, Kucheryavaya AY, et al,. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth Adult Lung and Heart-Lung Transplant Report-2011. J Heart Lung Transplant 2011; 30: 1104.
39. Christie JD, Edwards LB, Aurora P, et al,. The Registry of the International Society for Heart and Lung Transplantation: twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant 2009; 28: 1031.
40. ISHLT International Registry for Heart and Lung Transplantation [cited 2013 4/1]. Available at: http://www.ishlt.org/registries/heartLungRegistry.asp.
41. Palmer SM, Miralles AP, Lawrence CM, Gaynor JW, Davis RD, Tapson VF,. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 1999; 116: 127.
42. Hartwig MG, Snyder LD, Appel JZ, 3rd, et al,. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. J Heart Lung Transplant 2008; 27: 547.
43. Mullen JC, Oreopoulos A, Lien DC, et al,. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 2007; 26: 504.
44. Brock MV, Borja MC, Ferber L, et al,. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 2001; 20: 1282.
45. Ailawadi G, Smith PW, Oka T, et al,. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. J Thorac Cardiovasc Surg 2008; 135: 594.
46. Garrity ER Jr, Villanueva J, Bhorade SM, Husain AN, Vigneswaran WT,. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 2001; 71: 773.
47. Hachem RR, Chakinala MM, Yusen RD, et al,. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. J Heart Lung Transplant 2005; 24: 1320.
48. Burton CM, Andersen CB, Jensen AS, et al,. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J Heart Lung Transplant 2006; 25: 638.
49. Moffatt SD, Demers P, Robbins RC, et al,. Lung transplantation: a decade of experience. J Heart Lung Transplant 2005; 24: 145.
50. Swarup R, Allenspach LL, Nemeh HW, Stagner LD, Betensley AD,. Timing of basiliximab induction and development of acute rejection in lung transplant patients. J Heart Lung Transplant 2011; 30: 1228.
51. Goldfarb SB, Gaynor JW, Fuller S, et al,. Induction therapy with antithymocyte globulin before reperfusion. Ann Thorac Surg 2010; 90: 1110.
52. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2011 Annual Data Report.: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2012 [12/26/12]. Available at: http://srtr.transplant.hrsa.gov/annual-reports/2011/ pdf/2011-SRTR-ADR.pdf.
53. Fehr T, Sykes M,. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl Int 2008; 21: 1118.
54. Vincenti F, Larsen CP, Alberu J, et al,. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210.
55. Aoyama A, Ng CY, Millington TM, et al,. Comparison of lung and kidney allografts in induction of tolerance by a mixed-chimerism approach in cynomolgus monkeys. Transplant Proc 2009; 41: 429.
56. Gelman AE, Okazaki M, Lai J, et al,. CD4 + T lymphocytes are not necessary for the acute rejection of vascularized mouse lung transplants. J Immunol 2008; 180: 4754.
57. Dodd-o JM, Lendermon EA, Miller HL, et al,. CD154 blockade abrogates allospecific responses and enhances CD4(+) regulatory T-cells in mouse orthotopic lung transplant. Am J Transplant 2011; 11: 1815.